RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30146% above fair value

$1.16−0.06 (-4.92%)

Close on Nov 12, 2026Market cap $52.35MP/E –Yield –

Earnings

RenovoRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 29, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$1.07M

Non-GAAP basic earnings per share, Q3 FY2026

-$0.07

-$0.08 a year earlier

Latest guidance

Issued

Nov 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of RenovoRx's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 29, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 5, 2026after the close	$1.07M	–	-$0.08	-$0.07	Release
Q2 FY2026ended Jun 30, 2026	Aug 13, 2026after the close	$909.00K	+115.4%	-$0.06	-$0.05	Release
Q1 FY2026ended Mar 31, 2026	May 14, 2026after the close	$563.00K	+185.8%	-$0.09	-$0.08	Release
Q4 FY2025ended Dec 31, 2025	Mar 30, 2026after the close	–	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 13, 2025after the close	–	–	-$0.08	–	Release
Q2 FY2025ended Jun 30, 2025	Aug 14, 2025after the close	$422.00K	–	-$0.08	–	Release
Q1 FY2025ended Mar 31, 2025	May 15, 2025after the close	$197.00K	–	-$0.08	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 14, 2024before the open	–	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 14, 2023before the open	–	–	–	–	Release
Q2 FY2023ended Jun 30, 2023	Aug 17, 2023before the open	–	–	-$0.22	–	Release
Q1 FY2023ended Mar 31, 2023	May 15, 2023before the open	–	–	–	–	Release
Q4 FY2022ended Dec 31, 2022	Mar 2, 2023before the open	–	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 14, 2022before the open	–	–	–	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 15, 2022before the open	–	–	–	–	Release
Q1 FY2022ended Mar 31, 2022	May 16, 2022before the open	–	–	–	–	Release
Q4 FY2021ended Dec 31, 2021	Mar 30, 2022before the open	–	–	–	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 15, 2021after the close	–	–	–	–	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

RenovoRx's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
revenue	FY2026	$3.75M – $4.25M	$3.00M – $4.00M	Raised	Aug 13, 2026
revenue guidance	FY2026	$3.75M – $4.25M	–	New	Nov 5, 2026

Guidance history

Every forecast RenovoRx put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 5, 2026	revenue guidance	FY2026	$3.75M – $4.25M	New
Aug 13, 2026	revenue	FY2026	$3.75M – $4.25M	Raised
May 14, 2026	revenue	FY2026	$3.00M – $4.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.